Welcome to our dedicated page for Alto Neuroscience news (Ticker: ANRO), a resource for investors and traders seeking the latest updates and insights on Alto Neuroscience stock.
Alto Neuroscience develops clinical-stage precision medicines for neuropsychiatric disorders, using its Precision Psychiatry Platform™ to analyze EEG activity, neurocognitive assessments, wearable data and other biomarkers that may identify patient populations for its product candidates.
Company news centers on clinical data, trial initiations and pipeline decisions for programs including ALTO-207 in treatment-resistant depression and major depressive disorder, ALTO-101 in cognitive impairment associated with schizophrenia, and other candidates for bipolar depression, schizophrenia and mental health conditions. Updates also cover financial results, capital activity, regulatory designations, medical-meeting presentations and investor-conference participation.
Alto Neuroscience (ANRO) will participate in three investor-focused healthcare events in September 2026, featuring management presentations and discussions.
The company will join the H.C. Wainwright 28th Annual Global Healthcare Conference with a fireside chat and one-on-one meetings on September 14, 2026 at 9:30 a.m. ET, held in New York and virtually. Alto will present at Baird’s 2026 Global Healthcare Conference on September 15, 2026 at 9:40 a.m. ET in New York, followed by a fireside chat at TD Cowen’s 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026 at 3:00 p.m. ET, held virtually. Presentations will be available via live webcast and replay in the Investors section of Alto’s website.
Alto Neuroscience (NYSE: ANRO) has promoted Nick Smith to the combined role of president and chief financial officer, effective August 26, 2026. He will continue to lead finance and oversee corporate strategy and business development, reporting to founder and CEO Amit Etkin.
Smith joined Alto in 2021 as chief business officer and became CFO in 2022. According to Alto Neuroscience, he has led corporate development and capital strategy, including the company’s initial public offering, the May 2025 acquisition of ALTO-207, and subsequent financings supporting that program and the broader pipeline.
Alto Neuroscience (NYSE: ANRO) reported second quarter 2026 results, highlighted by expansion of ALTO-207 development and strengthened liquidity. An additional Phase 3 trial of ALTO-207 as monotherapy in treatment-resistant depression is planned for 2H 2027, alongside an ongoing potentially registrational Phase 2b adjunctive trial with topline data expected in 2H 2027.
Independent PRIME-PRAXOL data published in Nature Medicine showed significant pramipexole effects on anhedonia and depression, supporting the dopaminergic mechanism underlying ALTO-207. Alto completed an approximately $100 million equity financing in July 2026, resulting in pro forma cash of about $338 million, which is expected to fund planned operations through 2030. Phase 2b trials for ALTO-300 in major depressive disorder and ALTO-100 in bipolar depression remain on track for 2027 readouts. For Q2 2026, Alto reported R&D expenses of $22.1 million, G&A of $7.0 million, and a net loss of $27.6 million, with cash, cash equivalents, and restricted cash of $244.2 million as of June 30, 2026.
Alto Neuroscience (NYSE: ANRO) priced an underwritten registered direct offering of 3,776,436 common shares at $26.48 per share, for expected gross proceeds of about $100.0 million before fees. All shares are offered by Alto, and closing is targeted for July 14, 2026, subject to customary conditions.
According to Alto, net proceeds, together with existing cash, will be used to accelerate and expand clinical development of ALTO-207, including a planned additional Phase 3 monotherapy trial in treatment-resistant depression, and for general working capital. The financing is led by EcoR1 Capital with participation from new and existing healthcare investors.
Alto Neuroscience (NYSE: ANRO) highlighted a Nature Medicine publication of PRIME-PRAXOL, an independent, randomized, placebo-controlled trial of pramipexole in mood disorders with anhedonia.
Pramipexole significantly reduced anhedonia on SHAPS (Hedges’ g=0.62, p=0.006), with benefits on DARS and AES-S sustained over six months and larger effects in the MDD subgroup. High nausea rates (~60%) underscore the rationale for ALTO-207, which combines pramipexole with ondansetron; a potentially pivotal Phase 2b trial in treatment-resistant depression is ongoing with data expected in 2H 2027.
Alto Neuroscience (NYSE: ANRO) appointed Andrew Miller, Ph.D., founder of Karuna Therapeutics, to its Board of Directors effective May 27, 2026. Alto is a clinical-stage company developing precision medicines for neuropsychiatric disorders, including a potentially pivotal Phase 2b trial of ALTO-207 in treatment-resistant depression.
Dr. Miller led R&D at Karuna through its $14 billion acquisition by Bristol Myers Squibb, was lead inventor of KarXT/COBENFY for schizophrenia, and brings extensive neuropsychiatric drug development and corporate strategy experience to support Alto’s pipeline.
Alto Neuroscience (NYSE: ANRO) announced that founder and CEO Amit Etkin, M.D., Ph.D. received the Transformational Research Award from the Columbia University VP&S Alumni Association. The honor recognizes alumni making major biomedical research contributions within 25 years of graduation.
Etkin leads Alto’s Precision Psychiatry Platform and a clinical-stage pipeline in multiple mood and psychiatric disorders, with several mid- to late-stage data readouts anticipated over the next two years.
Alto Neuroscience (NYSE: ANRO) reported first quarter 2026 results and pipeline updates. Cash, cash equivalents and restricted cash were $264.2 million as of March 31, 2026, boosted by a $120 million PIPE, and are expected to fund planned operations through 2029.
Alto initiated a Phase 2b TRD trial for ALTO-207, with Phase 3 and potential NDA supported by current cash. The ALTO-101 Phase 2 POC trial missed its primary CIAS EEG endpoint but showed significant effects on several EEG markers of general cognition and sustained attention.
Enhanced eligibility and quality measures in the ALTO-300 and ALTO-100 Phase 2b trials are expected to improve data quality but shift topline readouts to 2027. Q1 2026 R&D expenses were $20.3 million, G&A $6.8 million, and net loss $26.2 million.
Alto Neuroscience (NYSE: ANRO) will participate in two upcoming investor conferences. Management will present at the Bank of America Securities Healthcare Conference on May 13, 2026, in Las Vegas and at the Jefferies Global Healthcare Conference on June 3, 2026, in New York.
Presentations will be available via live webcast and replay on Alto’s investor relations website.
Alto Neuroscience (NYSE: ANRO) presented Phase 2a data for ALTO-207 at the 2026 SOBP Annual Meeting on May 4, 2026. A randomized, single-blind, placebo-controlled trial (n=32) showed statistically significant antidepressant effects on MADRS and CGI-S through Week 8 and favorable tolerability.
Key metrics: mean pramipexole dose 4.1 mg by Day 8; 60% reached 5 mg by Day 12; MADRS effect sizes Week 6 d=1.67 (p=0.0004) and Week 8 d=1.1 (p=0.025); no ALTO-207 arm discontinuations during maintenance. Phase 2b is ongoing with topline expected in 2H 2027.